Last reviewed · How we verify
NCT03884127
Ezetimibe and Orlistat Affect the Intestinal Flora of Hyperlipidemia.
trial testing Ezetimibe 10mg in Hyperlipidemia in 58 participants. Status unknown.
30 August 2019
Quick facts
| Lead sponsor | Fifth Affiliated Hospital of Xinjiang Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 58 |
| Start date | 1 April 2019 |
| Primary completion | 30 August 2019 |
| Estimated completion | 30 September 2019 |
Drugs / interventions tested
- Ezetimibe 10mg — full drug profile →
- Orlistat 120 MG — full drug profile →
Conditions studied
- Hyperlipidemia — all drugs for Hyperlipidemia →
Sponsor
Fifth Affiliated Hospital of Xinjiang Medical University
Who can join
Adults 20 to 45, any sex, with Hyperlipidemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
At present,the prevalence of hyperlipidemia in Chinese adults is 40.40%,which is related to atherosclerotic cardiovascular disease and diabetes independent risk factors,while increasing the risk of cancer.Lipid metabolism affects the nutritional status of the intestinal epithelium,making the intestine Changes in the microenvironment of the intestinal flora affect the distribution of intestinal flora and eventually lead to bile acid metabolism change.Bile acid is a signal molecule that regulates glucose and lipid and energy metabolism in vivo State.The regulation of intestinal flora may be a new way to treat the imbalance of lipid metabolism,but it is currently sensitive to lipid metabolism the microbiome studies are unclear.In this study, newly diagnosed overweight patients with hyperlipidemia were treated with cholesterol absorption inhibition The drug intervention of ezeomab tablet and orlistat capsule for 12 weeks was observed to observe the changes of intestinal flora and bile acid metabolism after excessive cholesterol and triglyceride production.Clinical screening for the treatment of hyperlipidemia the study provides a reference for bacteria species and prevention and treatment,and provides a research basis for further development of drugs or foods that interfere with lipid metabolism by interfering with intestinal flora.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Distinctive Gut Microbiota in Patients with Overweight and Obesity with Dyslipidemia and its Responses to Long-term Orlistat and Ezetimibe Intervention: A Randomized Controlled Open-label Trial.
Jin J, Cheng R, Ren Y, Shen X, et al · · 2021 · cited 32× · PMID 34512358 · DOI 10.3389/fphar.2021.732541
Verify or expand the search:
- PubMed search for NCT03884127
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ezetimibe 10mg
Trials testing the same drug.
- NCT06547359 — A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects · Phase 1 · completed
- NCT05795517 — Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD） · Phase 2 · completed
- NCT05661552 — Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI · Phase 4 · completed
- NCT05970679 — Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A · Phase 3 · completed
- NCT05613400 — Statin and Bone Health · Phase 4 · unknown
Other recruiting trials for Hyperlipidemia
Currently open trials in the same condition.
- NCT06966258 — Inspire HER: Inspiring the Heart and Emotions for Radical Health · NA · recruiting
- NCT07216482 — A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) · Phase 3 · recruiting
- NCT06615609 — "Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Coronary Artery Bypass Graft · NA · recruiting
- NCT07400549 — Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support T · NA · recruiting
- NCT06603363 — Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03884127 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fifth Affiliated Hospital of Xinjiang Medical University
- Last refreshed: 21 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03884127.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing